All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA15
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
Valneva plans to accelerate pediatric development of its Lyme vaccine candidate, VLA15, in collaboration with Pfizer Inc. (NYSE: PFE), with the planned initiation of study VLA15-221 in the first quarter of 2021, subject to regulatory approval.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 30, 2020
Details:
This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking viral replication.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Avdoralimab
Therapeutic Area: Infections and Infectious Diseases Product Name: IPH5401
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
The study found that patients who progress towards severe COVID-19 disease, including those with severe pneumonia and acute respiratory distress syndrome (ARDS), exhibit an activation of the C5a/C5aR1 pathway.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nangibotide
Therapeutic Area: Infections and Infectious Diseases Product Name: LR12
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Nangibotide is a TREM-1 pathway inhibitor with multiple potential indications, such as septic shock and myocardial infarction. TREM-1 is an immunomodulatory receptor found on innate immune cells, which increases and maintains inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxaquin
Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
DNV3837 targets the treatment of Clostridioides difficile gastrointestinal infections (CDI), a pathogen classified as urgent threat by the U.S. Centers for Disease Control and Prevention (CDC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Innovation Council
Deal Size: $34.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2020
Details:
The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $308.0 million Upfront Cash: $130.0 million
Deal Type: Agreement June 08, 2020
Details:
Valneva and Pfizer will work closely together throughout the development of VLA15. The agreement was signed at the end of April 2020 to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA15
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $308.0 million Upfront Cash: $130.0 million
Deal Type: Collaboration April 30, 2020
Details:
Valneva and Pfizer will work closely together to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Avdoralimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
First patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
